Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

28.09 -0.21 (-0.74%)
Official Closing Price Updated: 7:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon
Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company. 
Via Benzinga
Top 3 Discounted Value Stocks Worth Buying Now
These stocks have a large cushion while retaining intrinsic value. 
Via Talk Markets
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC... 
Via Benzinga
Exposures Product Safety
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses
CSL and Arcturus Therapeutics report that their sa-mRNA COVID-19 vaccine, ARCT-154, delivered superior immunogenicity compared to Pfizer's Comirnaty in a Phase 3 study, persisting for one year and at a... 
Via Benzinga
Exposures COVID-19
Is Summit Therapeutics Stock a Buy?
Its alliance with a successful foreign biotech could be decisive for the stock. 
Via The Motley Fool
Pfizer Unusual Options Activity
Via Benzinga
Current Report: Pfizer (PFE)
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Over the past year, Pfizer's share price fell about 12.7% from $34.07 to $29.75 as of Wednesday’s... 
Via Talk Markets
15 Best Dividend Stocks for Lifelong Passive Income
These 15 dividend stocks can deliver stable passive income for life. 
Via The Motley Fool
3 Surprisingly Underrated Stocks to Buy Right Now
These stocks might look like bad picks. But appearances can be deceiving. 
Via The Motley Fool
Pfizer Voluntarily Withdraws Sickle Cell Disease Treatment Oxbryta From Global Market Due To Painful Disease Complication, Deaths
Pfizer has withdrawn Oxbryta from global markets and halted all clinical trials, citing safety concerns following clinical data that raised issues about fatal complications in sickle cell disease... 
Via Benzinga
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit.
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
2 High-Yield Dividend Stocks That Can Deliver a Lifetime of Passive Income
These two high-yield dividend stocks should deliver steady passive income for years to come. 
Via The Motley Fool
3 Ultra-High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Consider these three for a combination of dividend growth and a high yield. 
Via The Motley Fool
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets
From Pfizer Inc.
Via Business Wire
1 Ultra-High-Yield Healthcare Stock to Buy Hand Over Fist and 1 to Avoid
One of these is not like the other. 
Via The Motley Fool
3 Ultra-Cheap Stocks That Could Get a Boost From Fed Rate Cuts
These stocks are all trading at less than 12 times their estimated future earnings. 
Via The Motley Fool
Topics Economy
Exposures Interest Rates
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Ideaya Biosciences Stock Tumbles Despite Promising Data From Rare Eye Cancer Candidate
IDEAYA Biosciences released interim Phase 2 data that shows promising tumor shrinkage and eye preservation rates. 
Via Benzinga
2 Beaten-Down Stocks to Buy and Hold for a Decade
These innovative companies have the tools to rebound. 
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
3 Dirt Cheap Stocks to Buy Right Now
Bargain hunters should love these great stocks. 
Via The Motley Fool
Pfizer Advances On Its Cancer Journey
On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
Via Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:MRK),(NYSE:PFE),(NASDAQ:GLMD) EQNX::TICKER_END 
Via FinancialNewsMedia
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
From FN Media Group LLC
Via GlobeNewswire
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
From Pfizer Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Jim Cramer Labels Moderna A 'Big Disappointment,' But Suggests Doubling Down On Another Pharma Powerhouse
Jim Cramer likes Pfizer and recommends buying more stock. Six Flags is struggling, but Cramer likes First Solar and Equity Residential. Moderna has been disappointing, but Cramer likes Vertiv and... 
Via Benzinga
3 Magnificent Dividend Stocks With Yields Above 5% to Buy Now and Hold Forever
After underperforming over the past few years, these stocks offer huge dividend yields that could keep rising throughout your retirement. 
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
These biotech stocks have what it takes to be the biggest winners through the rest of the decade and beyond. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.